Notice: This company has been marked as potentially delisted and may not be actively trading. Seneca Biopharma (SNCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends SNCA vs. ADVM, CRDF, CRDL, CGEN, SCLX, OTLK, IPHA, CADL, VIGL, and JATTShould you be buying Seneca Biopharma stock or one of its competitors? The main competitors of Seneca Biopharma include Adverum Biotechnologies (ADVM), Cardiff Oncology (CRDF), Cardiol Therapeutics (CRDL), Compugen (CGEN), Scilex (SCLX), Outlook Therapeutics (OTLK), Innate Pharma (IPHA), Candel Therapeutics (CADL), Vigil Neuroscience (VIGL), and JATT Acquisition (JATT). These companies are all part of the "medical" sector. Seneca Biopharma vs. Adverum Biotechnologies Cardiff Oncology Cardiol Therapeutics Compugen Scilex Outlook Therapeutics Innate Pharma Candel Therapeutics Vigil Neuroscience JATT Acquisition Seneca Biopharma (NASDAQ:SNCA) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk. Do insiders and institutionals have more ownership in SNCA or ADVM? 5.2% of Seneca Biopharma shares are owned by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 2.1% of Seneca Biopharma shares are owned by insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is SNCA or ADVM more profitable? Adverum Biotechnologies has a net margin of 0.00% compared to Seneca Biopharma's net margin of -230.34%. Adverum Biotechnologies' return on equity of -65.14% beat Seneca Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Seneca Biopharma-230.34% -122.20% -110.61% Adverum Biotechnologies N/A -65.14%-40.52% Does the MarketBeat Community favor SNCA or ADVM? Adverum Biotechnologies received 354 more outperform votes than Seneca Biopharma when rated by MarketBeat users. However, 63.64% of users gave Seneca Biopharma an outperform vote while only 60.43% of users gave Adverum Biotechnologies an outperform vote. CompanyUnderperformOutperformSeneca BiopharmaOutperform Votes1463.64% Underperform Votes836.36% Adverum BiotechnologiesOutperform Votes36860.43% Underperform Votes24139.57% Which has more volatility and risk, SNCA or ADVM? Seneca Biopharma has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Do analysts prefer SNCA or ADVM? Adverum Biotechnologies has a consensus price target of $27.83, indicating a potential upside of 268.17%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Adverum Biotechnologies is more favorable than Seneca Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seneca Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has preferable valuation and earnings, SNCA or ADVM? Seneca Biopharma has higher earnings, but lower revenue than Adverum Biotechnologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeneca Biopharma$10K3,805.12-$8.35MN/AN/AAdverum Biotechnologies$3.60M43.68-$117.17M-$5.99-1.26 Does the media prefer SNCA or ADVM? In the previous week, Adverum Biotechnologies had 16 more articles in the media than Seneca Biopharma. MarketBeat recorded 16 mentions for Adverum Biotechnologies and 0 mentions for Seneca Biopharma. Seneca Biopharma's average media sentiment score of 0.00 beat Adverum Biotechnologies' score of -0.08 indicating that Seneca Biopharma is being referred to more favorably in the media. Company Overall Sentiment Seneca Biopharma Neutral Adverum Biotechnologies Neutral SummaryAdverum Biotechnologies beats Seneca Biopharma on 11 of the 16 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get Seneca Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SNCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNCA vs. The Competition Export to ExcelMetricSeneca BiopharmaBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.05M$3.12B$5.16B$8.94BDividend YieldN/A1.77%5.04%4.03%P/E RatioN/A29.57107.9916.24Price / Sales3,805.12312.801,298.8092.29Price / CashN/A179.8139.4036.42Price / Book1.654.446.425.98Net Income-$8.35M-$42.42M$115.02M$225.08M Seneca Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNCASeneca BiopharmaN/A$2.20-7.6%N/A+369.8%$38.05M$10,000.000.007Gap UpADVMAdverum Biotechnologies3.8022 of 5 stars$7.76-3.0%N/A-15.8%$166.42M$3.60M-1.30190Short Interest ↓CRDFCardiff Oncology1.2585 of 5 stars$3.46+12.3%N/A+214.0%$161.06M$665,000.00-3.6820Short Interest ↑CRDLCardiol Therapeutics2.8539 of 5 stars$1.96-1.5%N/A+151.3%$156.60M$60,000.00-5.9420Short Interest ↓News CoverageCGENCompugen2.8404 of 5 stars$1.74-2.2%N/A+177.3%$155.28M$33.46M-17.4068Earnings ReportShort Interest ↓News CoverageGap DownSCLXScilex3.5028 of 5 stars$0.80-9.1%N/A-40.4%$153.63M$50.83M-0.5680High Trading VolumeOTLKOutlook Therapeutics1.8305 of 5 stars$6.47+2.4%N/A-21.6%$153.08MN/A-0.6020IPHAInnate Pharma2.5369 of 5 stars$1.85+0.5%N/A-19.8%$149.79M$66.71M0.00220Analyst ForecastShort Interest ↑News CoverageGap DownCADLCandel Therapeutics0.2589 of 5 stars$4.65-3.7%N/A+395.0%$149.17M$120,000.00-2.7560Upcoming EarningsShort Interest ↑VIGLVigil Neuroscience3.3035 of 5 stars$3.70+3.6%N/A-34.9%$146.70MN/A-1.8064JATTJATT AcquisitionN/A$4.72+3.1%N/A+5.8%$140.76MN/A0.003Gap UpHigh Trading Volume Related Companies and Tools Related Companies Adverum Biotechnologies Alternatives Cardiff Oncology Alternatives Cardiol Therapeutics Alternatives Compugen Alternatives Scilex Alternatives Outlook Therapeutics Alternatives Innate Pharma Alternatives Candel Therapeutics Alternatives Vigil Neuroscience Alternatives JATT Acquisition Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNCA) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seneca Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seneca Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
